Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).

[1]  S. Yusuf,et al.  The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics , 2009, Clinical Research in Cardiology.

[2]  R. Doughty,et al.  A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study , 2009, Diabetologia.

[3]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[4]  G. Samsa,et al.  Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension , 2008, Annals of Internal Medicine.

[5]  P. Sleight.  The ONTARGET/TRANSCEND Trial Programme: baseline data , 2005, Acta Diabetologica.

[6]  A. Rogoza,et al.  Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension , 2005, The Journal of international medical research.

[7]  R. Babić,et al.  Ventricular and Vascular Remodelling – Effects of the Angiotensin II Receptor Blocker Telmisartan and/or the Angiotensin-Converting Enzyme Inhibitor Ramipril in Hypertensive Patients , 2005, The Journal of international medical research.

[8]  A. Mattioli,et al.  Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. , 2004, International journal of cardiology.

[9]  R. Doughty,et al.  Regeneration of the heart in diabetes by selective copper chelation. , 2004, Diabetes.

[10]  S. Yusuf,et al.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int , 2004, American heart journal.

[11]  S. Yusuf,et al.  Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. , 2004, Journal of the American College of Cardiology.

[12]  P. Capogrosso,et al.  Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study , 2004, Journal of Human Hypertension.

[13]  N. Reichek,et al.  Hypertension and Left Ventricular Hypertrophy : The 4 E Effects of Eplerenone , Enalapril , and Eplerenone / Enalapril in Patients With Essential , 2003 .

[14]  R. Schmieder,et al.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. , 2003, The American journal of medicine.

[15]  O. Simonetti,et al.  TrueFISP: Assessment of accuracy for measurement of left ventricular mass in an animal model , 2002, Journal of magnetic resonance imaging : JMRI.

[16]  Dudley J Pennell,et al.  Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance , 2002, Hypertension.

[17]  W. Tseng,et al.  Normal systolic and diastolic functions of the left ventricle and left atrium by cine magnetic resonance imaging. , 2002, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[18]  W. J. Hedley,et al.  Left ventricular mass and volume: fast calculation with guide-point modeling on MR images. , 2000, Radiology.

[19]  John S. Scott,et al.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.

[20]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[21]  V L Morgan,et al.  Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. , 1999, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[22]  G. Jennings,et al.  Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[23]  R. Schmieder,et al.  Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  J. Gottdiener,et al.  Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. , 1995, American journal of hypertension.

[25]  A. Roos,et al.  Evaluation of cardiac function with magnetic resonance imaging. , 1994, American heart journal.

[26]  A de Roos,et al.  Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. , 1993, Radiology.

[27]  N Reichek,et al.  Magnetic resonance imaging for assessment of myocardial function. , 1991, Magnetic resonance quarterly.

[28]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.